306 related articles for article (PubMed ID: 25473150)
1. New treatments for chronic hepatitis C: an overview for paediatricians.
Serranti D; Indolfi G; Resti M
World J Gastroenterol; 2014 Nov; 20(43):15965-74. PubMed ID: 25473150
[TBL] [Abstract][Full Text] [Related]
2. Treatment of hepatitis C virus genotype 3-infection.
Pol S; Vallet-Pichard A; Corouge M
Liver Int; 2014 Feb; 34 Suppl 1():18-23. PubMed ID: 24373074
[TBL] [Abstract][Full Text] [Related]
3. Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Bailly F; Pradat P; Virlogeux V; Zoulim F
Dig Dis; 2015; 33(4):613-23. PubMed ID: 26159282
[TBL] [Abstract][Full Text] [Related]
4. Targets for antiviral therapy of hepatitis C.
Rupp D; Bartenschlager R
Semin Liver Dis; 2014 Feb; 34(1):9-21. PubMed ID: 24782254
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.
Yau AH; Yoshida EM
Can J Gastroenterol Hepatol; 2014 Sep; 28(8):445-51. PubMed ID: 25229466
[TBL] [Abstract][Full Text] [Related]
6. Treatment of chronic hepatitis C: current and future.
Pawlotsky JM
Curr Top Microbiol Immunol; 2013; 369():321-42. PubMed ID: 23463207
[TBL] [Abstract][Full Text] [Related]
7. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals.
Dietz J; Susser S; Vermehren J; Peiffer KH; Grammatikos G; Berger A; Ferenci P; Buti M; Müllhaupt B; Hunyady B; Hinrichsen H; Mauss S; Petersen J; Buggisch P; Felten G; Hüppe D; Knecht G; Lutz T; Schott E; Berg C; Spengler U; von Hahn T; Berg T; Zeuzem S; Sarrazin C;
Gastroenterology; 2018 Mar; 154(4):976-988.e4. PubMed ID: 29146520
[TBL] [Abstract][Full Text] [Related]
8. Antiviral strategies in hepatitis C virus infection.
Sarrazin C; Hézode C; Zeuzem S; Pawlotsky JM
J Hepatol; 2012; 56 Suppl 1():S88-100. PubMed ID: 22300469
[TBL] [Abstract][Full Text] [Related]
9. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
10. Current progress in the treatment of chronic hepatitis C.
Alexopoulou A; Papatheodoridis GV
World J Gastroenterol; 2012 Nov; 18(42):6060-9. PubMed ID: 23155334
[TBL] [Abstract][Full Text] [Related]
11. Combinations of two drugs among NS3/4A inhibitors, NS5B inhibitors and non-selective antiviral agents are effective for hepatitis C virus with NS5A-P32 deletion in humanized-liver mice.
Doi A; Hikita H; Kai Y; Tahata Y; Saito Y; Nakabori T; Yamada R; Kodama T; Sakamori R; Murayama A; Nitta S; Asahina Y; Suemizu H; Tatsumi T; Kato T; Takehara T
J Gastroenterol; 2019 May; 54(5):449-458. PubMed ID: 30684016
[TBL] [Abstract][Full Text] [Related]
12. New hepatitis C virus (HCV) drugs and the hope for a cure: concepts in anti-HCV drug development.
Pawlotsky JM
Semin Liver Dis; 2014 Feb; 34(1):22-9. PubMed ID: 24782255
[TBL] [Abstract][Full Text] [Related]
13. New direct-acting antivirals' combination for the treatment of chronic hepatitis C.
Asselah T; Marcellin P
Liver Int; 2011 Jan; 31 Suppl 1():68-77. PubMed ID: 21205141
[TBL] [Abstract][Full Text] [Related]
14. The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Chatterji U; Garcia-Rivera JA; Baugh J; Gawlik K; Wong KA; Zhong W; Brass CA; Naoumov NV; Gallay PA
Antimicrob Agents Chemother; 2014 Jun; 58(6):3327-34. PubMed ID: 24687498
[TBL] [Abstract][Full Text] [Related]
15. The role of HCV proteins on treatment outcomes.
Kumthip K; Maneekarn N
Virol J; 2015 Dec; 12():217. PubMed ID: 26666318
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
[TBL] [Abstract][Full Text] [Related]
17. Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C.
Welch NM; Jensen DM
Liver Int; 2015 Jan; 35 Suppl 1():11-7. PubMed ID: 25529082
[TBL] [Abstract][Full Text] [Related]
18. The race for interferon-free HCV therapies: a snapshot by the spring of 2012.
De Clercq E
Rev Med Virol; 2012 Nov; 22(6):392-411. PubMed ID: 22936636
[TBL] [Abstract][Full Text] [Related]
19. Emerging therapies for hepatitis C.
Kim DY; Ahn SH; Han KH
Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
[TBL] [Abstract][Full Text] [Related]
20. The role of resistance in HCV treatment.
Vermehren J; Sarrazin C
Best Pract Res Clin Gastroenterol; 2012 Aug; 26(4):487-503. PubMed ID: 23199507
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
